Europe - BIT:1DXCM - US2521311074 - Common Stock
The current stock price of 1DXCM.MI is 59.05 EUR.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABL.DE | ABBOTT LABORATORIES | 24.97 | 186.44B | ||
| IUI1.DE | INTUITIVE SURGICAL INC | 63.2 | 167.66B | ||
| 1ISRG.MI | INTUITIVE SURGICAL INC | 54.14 | 143.61B | ||
| BSX.DE | BOSTON SCIENTIFIC CORP | 34.25 | 128.91B | ||
| 1BSX.MI | BOSTON SCIENTIFIC CORP | 35.31 | 127.13B | ||
| 2M6.DE | MEDTRONIC PLC | 16.95 | 103.27B | ||
| SHL.DE | SIEMENS HEALTHINEERS AG | 20.66 | 55.45B | ||
| BOX.DE | BECTON DICKINSON AND CO | 12.94 | 45.52B | ||
| EWL.DE | EDWARDS LIFESCIENCES CORP | 31.72 | 41.16B | ||
| 1PHIA.MI | KONINKLIJKE PHILIPS NV | 17.04 | 23.63B | ||
| DC4.DE | DEXCOM INC | 40.26 | 23.05B | ||
| PHI1.DE | KONINKLIJKE PHILIPS NV | 16.31 | 22.62B |
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
DEXCOM INC
6340 Sequence Drive
San Diego CALIFORNIA US
Employees: 10250
Phone: 18582000200
DexCom, Inc. is a medical device company, which engages in the design, development, and commercialization of glucose monitoring systems for ambulatory use by people with diabetes. The company is headquartered in San Diego, California and currently employs 10,300 full-time employees. The company went IPO on 2005-04-14. The firm is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The firm enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
The current stock price of 1DXCM.MI is 59.05 EUR. The price decreased by -2.78% in the last trading session.
1DXCM.MI does not pay a dividend.
1DXCM.MI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 1DXCM.MI.
ChartMill assigns a technical rating of 2 / 10 to 1DXCM.MI.
ChartMill assigns a fundamental rating of 6 / 10 to 1DXCM.MI. While 1DXCM.MI has a great profitability rating, there are some minor concerns on its financial health.
Over the last trailing twelve months 1DXCM.MI reported a non-GAAP Earnings per Share(EPS) of 1.46. The EPS decreased by -2.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 13.29% | ||
| ROA | 7.8% | ||
| ROE | 22.21% | ||
| Debt/Equity | 0.5 |
For the next year, analysts expect an EPS growth of 26.84% and a revenue growth 14.99% for 1DXCM.MI